Related Experiment Video
Updated: Aug 10, 2026
Generation of Murine Monoclonal Antibodies by Hybridoma Technology
Published on: January 2, 2017
Nucleic acid enzymes as a novel generation of anti-gene agents
1Institute for Cancer Research, Department of Immunology, The Norwegian Radium Hospital, Montebello, Oslo. mosioud@ulrik.uio.no
Abstract:
Recent molecular and cellular studies have highlighted the important role of some gene products in the cause and/or perpetuation of human pathological conditions including cancer and autoimmune diseases. The identification of such gene products has led to the development of new candidate therapies. The discovery of catalytic nucleic acid enzymes has provided researchers with a potentially important tool to block the expression of abnormal genes, provided that their sequences are known. The cleavage specificity of these compounds is determined by their hybridizing antisense arms, which anneal with the target mRNA in a complementary fashion. Nucleic acid enzymes can be delivered to cells either endogenously as gene encoding RNA enzymes (ribozymes) or exogenously as in vitro made agents. Given the progress reported during the last years, a wide range of molecular designs and chemical modifications can be introduced into these compounds, in particular the hammerhead type ribozyme. Here, we review the design, stability and the therapeutic application of these agents with the goals of illustrating relevant gene targets and signal pathways for molecular medicine. Relevant in vivo problems of the technology, mRNA repair by group I intron ribozymes and gene regulation by endogenous RNA will also be discussed.
Insights
Catalytic nucleic acid enzymes, like hammerhead ribozymes, offer a novel therapeutic approach by blocking abnormal gene expression. These agents show promise for treating diseases such as cancer and autoimmune disorders.
Area of Science:
- Molecular Biology
- Biochemistry
- Therapeutics
Background:
- Gene products play critical roles in human diseases like cancer and autoimmune conditions.
- Identifying these gene products enables the development of targeted therapies.
- Catalytic nucleic acid enzymes (ribozymes) are emerging tools for blocking abnormal gene expression.
Purpose of the Study:
- To review the design, stability, and therapeutic applications of RNA enzymes, particularly hammerhead ribozymes.
- To illustrate relevant gene targets and signaling pathways for molecular medicine.
- To discuss challenges and future directions in RNA enzyme technology.
Main Methods:
- Review of recent molecular and cellular studies on RNA enzymes.
- Analysis of ribozyme design, including hybridization-based cleavage specificity.
- Discussion of endogenous and exogenous delivery methods for RNA enzymes.
Main Results:
- Hammerhead ribozymes can be designed with specific cleavage activity against target mRNAs.
- Chemical modifications enhance the stability and therapeutic potential of RNA enzymes.
- RNA enzymes represent a versatile platform for gene silencing and molecular medicine.
Conclusions:
- RNA enzymes offer a promising strategy for developing novel therapeutics against various diseases.
- Further research into in vivo applications and overcoming delivery challenges is crucial.
- This technology holds significant potential for advancing molecular medicine and gene regulation strategies.
Related Concept Videos
01:09Recombinant DNA
02:47Ribozymes
Ribozymes can be...
01:20The Central Dogma
RNA is the Missing Link Between DNA and Proteins
In the early 1900s, scientists discovered that DNA stores all the information needed for cellular functions and that proteins perform most of these functions. However, the mechanisms of converting genetic information into functional proteins remained unknown for many years. Initially, it was believed that a single gene is...
01:31Hybridoma Technology
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...